| Name | Lomtegovimab |
|---|
| Description | Lomtegovimab (BI 767551) is a humanized anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Lomtegovimab 靶向 SARS-CoV-2 S 的 RBD,KD 值为 1.09 nM[2]。 Lomtegovimab 显示中和活性,对 SARS-CoV-2 S D614G, SARS-CoV-2 S B.1.1.7, SARS-CoV-2 BavPat1 (B.1) 的 IC50 值分别为 0.001、0.001、0.010 µg/mL[2]。 |
| In Vivo | Lomtegovimab (40 mg/kg;i.p. 或 i.n.;一次;感染前三天) 保护 hACE2 转导的小鼠免受 SARS-CoV-2 感染[2]。 Animal Model: BALB/c mice (Ad_ACE2-mCherry)[2] Dosage: 40 mg/kg Administration: I.p. or I.n.; once; three days before infection Result: Led to a complete neutralization of infectious SARS-CoV-2 and slightly reduced amounts of viral RNA in the lungs of treated animals. |
| References |
| No Any Chemical & Physical Properties |